

**ASX Release**

**Oventus presentation for AGM of Thorney Technologies Ltd**

Brisbane, Australia 24<sup>th</sup> November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors at the Annual General Meeting of Thorney Technologies Ltd (ASX: TEK) today in Melbourne.

Dr Chris Hart said “We are lucky to be supported by an institution with the pedigree of Thorney. We’ve had an incredible response following Thorney’s Chairman, Alex Waislitz’s presentation on Oventus at last week’s Sohn Hearts and Minds conference in Sydney and are grateful of the opportunity to present directly to investors today.”

**About the Oventus O<sub>2</sub>Vent airway technology**

The Oventus O<sub>2</sub>Vent is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, minimising pressure swings during sleep.

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

—ENDS—

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: 0403 003 475

Jane Lowe, IR Department: M: 0411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**About Oventus**

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O<sub>2</sub>Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

A clinical study completed earlier this year showed the company's first generation product, the O<sub>2</sub>Vent Mono™, is successful in treating Obstructive Sleep Apnoea (OSA) and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.<sup>3</sup>

<sup>1</sup> Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

<sup>2</sup> Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

<sup>3</sup> Sutherland et al. *Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*



# Oventus: Innovators in Sleep Apnoea Treatment

Presentation to investors at  
the 2017 AGM of Thorney  
Technologies Ltd (ASX:  
TEK)

November 2017




## About Oventus (ASX: OVN)

Oventus is commercializing its O<sub>2</sub>Vent technology to treat Obstructive Sleep Apnoea

Our titanium, 3D printed airway technology “O<sub>2</sub>Vent” enhances treatment outcomes **for more than half** of OSA patients





A close-up photograph of a man with dark hair and a beard, sleeping in a hospital bed. He is wearing a white medical device that covers his nose and mouth, secured with straps around his head and chin. The device has a clear plastic filter or tube attached to the bottom. He is lying on a light-colored pillow, and a blue blanket is visible over his shoulder. The background shows a white hospital sheet and a green wall.

Without the need  
for one of these

A photograph of a bed with a light-colored wooden headboard. Three white pillows are arranged against the headboard. The top pillow is slightly behind the other two. The bottom two pillows are in the foreground, with the one on the right being the primary focus for the text overlay. The bed is covered with a white sheet.

# Obstructive sleep apnoea... more than just a poor night's sleep

**OSA impacts the way  
people breathe when they  
are sleeping.**

**Breathing is briefly  
interrupted or becomes very  
shallow during sleep.**

A light gray world map serves as the background. Five colored location pins are placed on the map: three in the Northern Hemisphere (North America, Europe, and East Asia) and two in the Southern Hemisphere (Australia and South America).

## Poor sleep has major impacts on health economics

A blue circle containing the text "80%".

80%

Number of sleep apnoea sufferers understood to be out of care right now

An orange circle containing the text "\$26.2 BILLION".

\$26.2  
BILLION

Financial losses in Australia between 2016-2017 from inadequate sleep

A dark blue circle containing the text "\$40.1 BILLION".

\$40.1  
BILLION

Australia attributed \$40.1 billion to loss of well-being in 2016-2017




# The big business of sleep

A photograph of a man and a woman in bed. The woman, on the left, is sleeping with her mouth wide open, indicating a possible sleep apnea episode. The man, on the right, is awake and looking upwards with a concerned expression. They are lying on a bed with blue and white striped pillows.

Obstructive Sleep Apnoea (OSA) is a massive market.  
It is worth US\$3.8\*\* globally, growing at a CAGR of 15-20%.

\*\* In 2015: Sleep Apnea Diagnostic & Therapeutic  
Devices Market, Markets and Markets, Table 98.



Only 20% of OSA sufferers  
are in care.

Why?

Their inability to tolerate  
conventional treatment.



Does this look  
comfortable to you?



# How Oventus Airway technology works

The O<sub>2</sub>Vent technology is the first major innovation in the treatment of sleep apnoea for years

1.

Air goes in through the airway on inhalation and out through the airway on exhalation.

Acts like a “second nose” when patient’s mouth is closed. An open mouth is undesirable when sleeping as an open jaw can cause breathing obstruction in the throat.



2.

Air in on inhalation delivered to throat, air out on exhalation

3.

The device brings the lower jaw forward, making more room for air to go into the patient’s lungs



## Compelling clinical data

In clinical trials (and in real life) our devices succeeded where others could not.

### **Oventus Airway Technology:**

- Makes mouth guards 30-50% more efficacious, and
- Dramatically reduces CPAP pressures and eliminates the need for masks, which
- Delivers significant competitive advantages for half of the current mouth guard and mask market of \$3.8billion/year, and

**With the ability to bring more patients into care may well dramatically increase this addressable market**

100%

Patients experienced significant improvement in snoring using O<sub>2</sub>Vent

82%

Patients experienced complete elimination of snoring using O<sub>2</sub>Vent

76%

Patients decreased their Apnoea-Hypopnea Index (AHI) using O<sub>2</sub>Vent

With Oventus' oral device, many patients reported a good night's sleep...  
*for the first time in **decades**.*



# Distribution agreement with Modern Dental Group... the world's largest distributor of dental prosthetics

MODERN DENTAL GROUP LOCATIONS



## Modern Dental is listed on HKSE

Ticker: 3600 | Market cap: \$2.21 b

Has 25% coverage of all dentists in USA  
(34,000 dental offices through subsidiary, Microdental)

Top 3 market share in all major European countries

Australia's largest dental laboratory network

70+ sales and customer service centres overseas

Focus on custom-made prostheses

Oventus' range is **the only premium device range** that Modern will sell

# Corporate snapshot

## Oventus Medical Limited: ASX:OVN

### Capital Structure

Shares on Issue	92.1m
Options	3.84m
Price (22/11/17)	\$0.61
Market Cap	\$56.20m

Cash on hand (30/6/17)	\$8,663,000
Revenue FY17	\$447,994







**"I HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING.**

No snoring and so easy to carry around. Used it right through Europe and did not have to worry about electricity or extra bags. Used a CPAP for 20 years. Now I am so free from all that. I love it!"

**Jeanne Marshall**

See more at [www.oventus.com.au](http://www.oventus.com.au)